# 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY

A. 510(k) Number: K173691

# B. Purpose for Submission:

To obtain a substantial equivalence determination for the Sofia Lyme FIA for use with Sofia 2 analyzers

C. Measurand: IgM antibodies to Borrelia burgdorferi proteins IgG antibodies to Borrelia burgdorferi proteins

D. Type of Test: Fluorescent immunoassay (FIA), bi-directional lateral flow format

E. Applicant: Quidel Corporation

F. Proprietary and Established Names: Sofia Lyme FIA

# G. Regulatory Information:

1. Regulation section:   
21 CFR 866.3830

2. Classification: Class II

3. Product code: LSR; Reagent, Borrelia Serological Reagent

4. Panel:

# Immunology and Microbiology Devices

# H. Intended Use:

1. Intended use(s):

The Sofia Lyme FIA employs immunofluorescence for the rapid differential detection of human IgM and IgG antibodies to Borrelia burgdorferi from serum and plasma specimens from patients suspected of $B _ { \cdot }$ . burgdorferi infection. This qualitative test is intended for use as an aid in the diagnosis of Lyme disease. A negative result does not preclude infection with $B$ . burgdorferi. All positive results for IgM and/or IgG should be further tested by a corresponding second-tier western blot assay. Test results are to be used in conjunction with information obtained from the patient’s clinical evaluation and other diagnostic procedures.

The Sofia Lyme FIA may be used with Sofia or Sofia 2.

2. Indication(s) for use: Same as Intended Use(s)

3. Special conditions for use statement(s): Not Applicable (N/A)

4. Special instrument requirements: Sofia 2 Instrument

# I. Device Description:

The Sofia Lyme FIA is an immunofluorescence-based, lateral flow assay for detection of IgM and/or IgG antibodies to Borrelia burgdorferi in patient specimens. Reagents for the assay are ready-to-use and provided in the kit.

The assay uses a bidirectional test strip format to detect both IgM and IgG antibodies to $B$ . burgdorferi. One side of the test strip detects IgM antibodies to $B _ { \cdot }$ . burgdorferi and the other side of the test strip detects IgG antibodies to B. burgdorferi.

To perform the test, a patient serum or plasma specimen is obtained and added to a pre-filled vial containing the Lyme running buffer. The diluted sample is then pipetted into the round sample port in the center of the Test Cassette.

The Test Cassette is loaded into Sofia 2 in either the READ NOW Mode or WALK AWAY Mode. In READ NOW Mode, the user allows the cassette to develop on the countertop for 10 minutes. In WALK AWAY Mode, the user immediately after adding the specimen to the cassette, the cassette is inserted into Sofia 2. Sofia 2 will analyze the test strip at 3, 5, 8, and 10 minutes until both IgM and IgG positive results are received. This feature allows for earlier read times.

Each Sofia Lyme FIA kit will contain one Positive and one Negative Control—each provided in separate dropper bottles. The Positive QC control is formulated with patient Lyme IgM and IgG positive plasma diluted into 1X PBS, and $0 . 3 \%$ Microcide is added to the solution as an antimicrobial. The Negative QC control is formulated with patient negative serum diluted into 1X PBS and $0 . 3 \%$ Microcide is added to the solution as an antimicrobial. External Controls will be tested by adding 2 drops to the test cassette.

# J. Substantial Equivalence Information:

1. Predicate device name(s):

Vidas Lyme IgM Vidas Lyme IgG2.

Predicate 510(k) number(s):

K122979   
K122986

3. Comparison with predicate:

<table><tr><td colspan="1" rowspan="1">Item</td><td colspan="1" rowspan="1">Proposed Device</td><td colspan="1" rowspan="1">Predicate IgM Device</td><td colspan="1" rowspan="1">Predicate IgG Device</td></tr><tr><td colspan="1" rowspan="1">Features</td><td colspan="1" rowspan="1">Sofia Lyme FIA withSofia 2</td><td colspan="1" rowspan="1">bioMerieux Vidas LymeIgM</td><td colspan="1" rowspan="1">bioMerieux Vidas LymeIgG</td></tr><tr><td colspan="1" rowspan="1">IntendedUse</td><td colspan="1" rowspan="1">The Sofia Lyme FIAemploysimmunofluorescence forthe rapid differentialdetection of human IgMand IgG antibodies toBorrelia burgdorferi fromserum and plasmaspecimens from patientssuspected of B. burgdorferiinfection. This qualitativetest is intended for use asan aid in the diagnosis ofLyme disease. A negativeresult does not precludeinfection with B.burgdorferi. All positiveresults for IgM and/or IgGshould be further tested bya corresponding second-tierwestern blot assay. Testresults are to be used in</td><td colspan="1" rowspan="1">The VIDAS Lyme IgMassay is an automatedqualitative enzymeimmunoassay intended foruse on the instruments ofthe VIDAS family in thepresumptive detection ofhuman IgG antibodies toBorrelia burdorferi inhuman serum or plasma. Itshould be used to testpatients with a historyand/or symptoms ofinfection with B.burgdorferi. All VIDASLyme IgG positivespecimens should be furthertested with a Western BlotIgG assay to obtainsupportive evidence ofinfection with B.burgdorferi.</td><td colspan="1" rowspan="1">The VIDAS Lyme IgGassay is an automatedqualitative enzymeimmunoassay intended foruse on the instruments ofthe VIDAS family in thepresumptive detection ofhuman IgG antibodies toBorrelia burdorferi inhuman serum or plasma. Itshould be used to testpatients with a historyand/or symptoms ofinfection with B.burgdorferi. All VIDASLyme IgG positivespecimens should be furthertested with a Western BlotIgG assay to obtainsupportive evidence ofinfection with B.burgdorferi.</td></tr><tr><td colspan="1" rowspan="1">b</td><td colspan="1" rowspan="1">conjunction withinformation obtained fromthe patient's clinicalevaluation and otherdiagnostic procedures.The Sofia Lyme FIA may beused with Sofia or Sofia 2.</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">Instrument</td><td colspan="1" rowspan="1">Sofia 2 (and Sofia)</td><td colspan="1" rowspan="1">VIDAS and miniVIDAS</td><td colspan="1" rowspan="1">VIDAS and miniVIDAS</td></tr><tr><td colspan="1" rowspan="1">Analyte</td><td colspan="1" rowspan="1">Human IgM and IgGantibodies against B.burgdorferi proteins</td><td colspan="1" rowspan="1">Human IgM antibodiesagainst B. burgdorferiproteins</td><td colspan="1" rowspan="1">Human IgG antibodiesagainst B. burgdorferiproteins</td></tr><tr><td colspan="1" rowspan="1">AutomatedAnalysis</td><td colspan="1" rowspan="1">Yes</td><td colspan="1" rowspan="1">Yes</td><td colspan="1" rowspan="1">Yes</td></tr><tr><td colspan="1" rowspan="1">ReadResults</td><td colspan="1" rowspan="1">Read results on instrumentscreen or print with optionalprinter</td><td colspan="1" rowspan="1">Result report is printed</td><td colspan="1" rowspan="1">Result report is printed</td></tr><tr><td colspan="1" rowspan="1">ReadResultTime</td><td colspan="1" rowspan="1">Sofia 2 - Potential for earlyread in Walk-Away Modewith Sofia 2. Sofia 2 willimage cassette at 3, 5, 8, and10 minutes until both IgMand IgG positive results arereceived.Sofia - 10 minutes</td><td colspan="1" rowspan="1">27 minutes</td><td colspan="1" rowspan="1">27 minutes</td></tr><tr><td colspan="1" rowspan="1">SpecimenTypes</td><td colspan="1" rowspan="1">Serum and plasma</td><td colspan="1" rowspan="1">Serum and plasma</td><td colspan="1" rowspan="1">Serum and plasma</td></tr><tr><td colspan="1" rowspan="1">Qualitative</td><td colspan="1" rowspan="1">Yes</td><td colspan="1" rowspan="1">Yes</td><td colspan="1" rowspan="1">Yes</td></tr><tr><td colspan="1" rowspan="1">TestPrinciple</td><td colspan="1" rowspan="1">Immunofluorescence Device</td><td colspan="1" rowspan="1">ImmunofluorescenceDevice</td><td colspan="1" rowspan="1">ImmunofluorescenceDevice</td></tr><tr><td colspan="1" rowspan="1">Format</td><td colspan="1" rowspan="1">Lateral-flow Bi-directionalTest Cassette</td><td colspan="1" rowspan="1">Enzyme-linked fluorescentassay (ELFA)</td><td colspan="1" rowspan="1">Enzyme-linked fluorescentassay (ELFA)</td></tr><tr><td colspan="1" rowspan="1">AntibodiesUsed</td><td colspan="1" rowspan="1">Monoclonal anti-human IgGand polyclonal anti-humanIgM</td><td colspan="1" rowspan="1">Anti-human IgM antibodies</td><td colspan="1" rowspan="1">Anti-human IgG antibodies</td></tr><tr><td colspan="1" rowspan="1">AntigensUsed</td><td colspan="1" rowspan="1">Recombinant Proteins andsynthetic peptides of B.burgdorferi</td><td colspan="1" rowspan="1">Recombinant proteins of B.burgdorferi</td><td colspan="1" rowspan="1">Recombinant proteins of B.burgdorferi</td></tr><tr><td colspan="1" rowspan="1">DetectionMethod</td><td colspan="1" rowspan="1">Polystyrene microparticlesdyed with Europium chelate</td><td colspan="1" rowspan="1">Alkaline phosphatase/4-MUP</td><td colspan="1" rowspan="1">Alkaline phosphatase/4-MUP</td></tr><tr><td colspan="1" rowspan="1">Storage</td><td colspan="1" rowspan="1">Room Temperature (15-30°C)</td><td colspan="1" rowspan="1">2-8</td><td colspan="1" rowspan="1">2-8</td></tr><tr><td colspan="1" rowspan="1">Running</td><td colspan="1" rowspan="1">One pre-filled vial containing</td><td colspan="1" rowspan="1">Sample diluent and wash</td><td colspan="1" rowspan="1">Sample diluent and wash</td></tr><tr><td colspan="1" rowspan="1">BufferSolution</td><td colspan="1" rowspan="1">PBS</td><td colspan="1" rowspan="1">buffer</td><td colspan="1" rowspan="1">buffer</td></tr><tr><td colspan="1" rowspan="1">QualityControlFeatures</td><td colspan="1" rowspan="1">Built-in features include:Built-in procedural controlzone scanned by the analyzerto determine whetheradequate flow occurred onthe IgG side of the assay.Built-in reference controlline scanned by the analyzerto determine whetheradequate flow occurred onthe IgM side of the assay.Analyzer prevents used orexpired cartridge from beingread by the readerCassette must be properlyinserted</td><td colspan="1" rowspan="1">One positive and onenegative control areincluded and must be testedafter opening a new kit tomonitor reagent failure.</td><td colspan="1" rowspan="1">One positive and onenegative control areincluded and must be testedafter opening a new kit tomonitor reagent failure.</td></tr></table>

# K. Standard/Guidance Document Referenced (if applicable):

Establishing the Performance Characteristics of In Vitro Diagnostic Devices for the Detection of Antibodies to Borrelia burgdorferi

L. Test Principle: Immunofluorescence

# M. Performance Characteristics (if/when applicable):

1. Analytical performance:

a. Precision/Reproducibility:

The precision of the Sofia Lyme FIA with Sofia 2 was evaluated at one Quidel site utilizing 2 operators and 2 Sofia 2 instruments. Contrived samples were prepared at levels that ranged from negative to moderate positive for both IgM and IgG. Each sample was tested by 2 operators in duplicate with a total of 24 different runs (2 runs per day over a total of 12 days) for a total of 96 times over the course of the study. See Tables 1 and 2 for results.

Table 1. Sofia Lyme FIA with Sofia 2 Precision – Within Run   

<table><tr><td rowspan=2 colspan=1>IgM or IgG Sample</td><td rowspan=1 colspan=2>IgM Positive</td><td rowspan=2 colspan=1>IgM % PositivityTotal (n=96)</td><td rowspan=1 colspan=2>IgG Positive</td><td rowspan=2 colspan=1>IgG % PositivityTotal (n=96)</td></tr><tr><td rowspan=1 colspan=1>Run 1</td><td rowspan=1 colspan=1>Run 2</td><td rowspan=1 colspan=1>Run 1</td><td rowspan=1 colspan=1>Run 2</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>0/48</td><td rowspan=1 colspan=1>0/48</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0/48</td><td rowspan=1 colspan=1>0/48</td><td rowspan=1 colspan=1>0%</td></tr><tr><td rowspan=1 colspan=1>High Negative (C5)</td><td rowspan=1 colspan=1>0/48</td><td rowspan=1 colspan=1>0/48</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0/48</td><td rowspan=1 colspan=1>0/48</td><td rowspan=1 colspan=1>0%</td></tr><tr><td rowspan=1 colspan=1>Low Positive (C95)</td><td rowspan=1 colspan=1>48/48</td><td rowspan=1 colspan=1>48/48</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>48/48</td><td rowspan=1 colspan=1>46/48</td><td rowspan=1 colspan=1>100%</td></tr><tr><td rowspan=1 colspan=1>Moderate Positive (2-3X)</td><td rowspan=1 colspan=1>48/48</td><td rowspan=1 colspan=1>48/48</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>48/48</td><td rowspan=1 colspan=1>48/48</td><td rowspan=1 colspan=1>100%</td></tr></table>

Table 2. Sofia Lyme FIA with Sofia 2 Precision – Between Operator   

<table><tr><td rowspan=2 colspan=1>IgM or IgG Sample</td><td rowspan=1 colspan=2>% IgM Positivity</td><td rowspan=1 colspan=1>IgM % Positivity</td><td rowspan=1 colspan=2>% IgG Positivity</td><td rowspan=2 colspan=1>IgG % PositivityTotal (n=96)</td></tr><tr><td rowspan=1 colspan=1>Operator1</td><td rowspan=1 colspan=1>Operator 2</td><td rowspan=1 colspan=1>Total (n=96)</td><td rowspan=1 colspan=1>Operator 1</td><td rowspan=1 colspan=1>Operator 2</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>0/48</td><td rowspan=1 colspan=1>0/48</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0/48</td><td rowspan=1 colspan=1>0/48</td><td rowspan=1 colspan=1>0%</td></tr><tr><td rowspan=1 colspan=1>High Negative (C5)</td><td rowspan=1 colspan=1>0/48</td><td rowspan=1 colspan=1>0/48</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0/48</td><td rowspan=1 colspan=1>0/48</td><td rowspan=1 colspan=1>0%</td></tr><tr><td rowspan=1 colspan=1>Low Positive (C95)</td><td rowspan=1 colspan=1>48/48</td><td rowspan=1 colspan=1>48/48</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>48/48</td><td rowspan=1 colspan=1>48/48</td><td rowspan=1 colspan=1>100%</td></tr><tr><td rowspan=1 colspan=1>Moderate Positive (2-3X)</td><td rowspan=1 colspan=1>48/48</td><td rowspan=1 colspan=1>48/48</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>48/48</td><td rowspan=1 colspan=1>48/48</td><td rowspan=1 colspan=1>100%</td></tr></table>

The reproducibility of the Sofia Lyme FIA with Sofia 2 was evaluated at 3 different laboratories, 1 of which was Quidel. Two operators at each site tested a series of coded, contrived samples ranging from negative to moderate positive IgM and IgG concentrations. Testing occurred for a minimum of 5 separate days, spanning a period of approximately 2 weeks. See Table 3 for results.

Table 3. Sofia Lyme FIA with Sofia 2 Reproducibility Study Inter-laboratory Agreement   

<table><tr><td rowspan=1 colspan=1>Site</td><td rowspan=1 colspan=1>IgMNegative(C0)</td><td rowspan=1 colspan=1>IgM HighNegative(C5)</td><td rowspan=1 colspan=1>IgM LowPositive(C95)</td><td rowspan=1 colspan=1>IgMModeratePositive(2-3X LOD)</td><td rowspan=1 colspan=1>IgGNegative(C0)</td><td rowspan=1 colspan=1>IgG HighNegative(C5)</td><td rowspan=1 colspan=1>IgG LowPositive(C95)</td><td rowspan=1 colspan=1>IgGModeratePositive(2-3X LOD)</td></tr><tr><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>30/30</td><td rowspan=1 colspan=1>30/30</td><td rowspan=1 colspan=1>30/30</td><td rowspan=1 colspan=1>30/30</td><td rowspan=1 colspan=1>30/30</td><td rowspan=1 colspan=1>30/30</td><td rowspan=1 colspan=1>30/30</td><td rowspan=1 colspan=1>30/30</td></tr><tr><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>30/30</td><td rowspan=1 colspan=1>30/30</td><td rowspan=1 colspan=1>30/30</td><td rowspan=1 colspan=1>30/30</td><td rowspan=1 colspan=1>30/30</td><td rowspan=1 colspan=1>30/30</td><td rowspan=1 colspan=1>30/30</td><td rowspan=1 colspan=1>30/30</td></tr><tr><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>30/30</td><td rowspan=1 colspan=1>30/30</td><td rowspan=1 colspan=1>27/30</td><td rowspan=1 colspan=1>28/30</td><td rowspan=1 colspan=1>30/30</td><td rowspan=1 colspan=1>30/30</td><td rowspan=1 colspan=1>25/30</td><td rowspan=1 colspan=1>30/30</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>90/90</td><td rowspan=1 colspan=1>90/90</td><td rowspan=1 colspan=1>87/90</td><td rowspan=1 colspan=1>88/90</td><td rowspan=1 colspan=1>90/90</td><td rowspan=1 colspan=1>90/90</td><td rowspan=1 colspan=1>85/90</td><td rowspan=1 colspan=1>90/90</td></tr><tr><td rowspan=1 colspan=1>% OverallAgreement(95% CI)</td><td rowspan=1 colspan=1>100%(95.1-100%)</td><td rowspan=1 colspan=1>100%(95.1-100%)</td><td rowspan=1 colspan=1>96.7%(90.3-99.3%)</td><td rowspan=1 colspan=1>97.8%(91.8-99.9%)</td><td rowspan=1 colspan=1>100%(95.1-100%)</td><td rowspan=1 colspan=1>100%(95.1-100%)</td><td rowspan=1 colspan=1>94.4%(87.3-97.9%)</td><td rowspan=1 colspan=1>100%(95.1-100%)</td></tr></table>

$b$ . Linearity/assay reportable range: Not applicable (N/A)

c. Traceability, Stability, Expected values (controls, calibrators, or methods): N/A

d. Detection limit: N/A e. Analytical specificity:

To determine the analytical specificity of the Sofia Lyme FIA with Sofia 2, 200 seemingly healthy individuals with no known history of physician-diagnosed Lyme disease were evaluated. Half of the samples (100) were collected from a non-endemic Lyme region while the other half of the samples (100) were collected from an

endemic Lyme region of the United States. Samples were tested on Sofia Lyme FIA and the predicate Lyme IgM and $\mathrm { I g G }$ assays. The Analytical Specificity results for Sofia Lyme FIA and the predicate devices are summarized in Table 4.

Table 4. Sofia Lyme FIA with Sofia 2 and Predicate Analytical Specificity   

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>Sofia IgM(% negative results)</td><td rowspan=1 colspan=1>Predicate IgM*(% negative results)</td><td rowspan=1 colspan=1>Sofia IgG(% negative results)</td><td rowspan=1 colspan=1>Predicate IgG(% negative results)</td></tr><tr><td rowspan=1 colspan=1>Endemic</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>86.0%</td><td rowspan=1 colspan=1>80.0%</td><td rowspan=1 colspan=1>95.0%</td><td rowspan=1 colspan=1>98.0%</td></tr><tr><td rowspan=1 colspan=1>Non-Endemic</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>93.0%</td><td rowspan=1 colspan=1>93.0%</td><td rowspan=1 colspan=1>98.0%</td><td rowspan=1 colspan=1>99.0%</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>200</td><td rowspan=1 colspan=1>89.5%</td><td rowspan=1 colspan=1>86.5%</td><td rowspan=1 colspan=1>96.5%</td><td rowspan=1 colspan=1>98.5%</td></tr></table>

\*Equivocal results were considered Positive.

f. Assay cut-off: N/A

# i. Matrix Effects:

The purpose of this study is to compare plasma and serum using Sofia Lyme FIA with Sofia 2. Paired samples were used to compare matrix performance. The specimens tested were from non-selected prospectively collected donors, targeting 60 IgG positive and $6 0 ~ \mathrm { I g M }$ positive samples and selected (known positive) prospectively collected donors, targeting $6 0 \mathrm { I g G }$ positive and $6 0 ~ \mathrm { I g M }$ positive samples.

Table 5. Sofia Lyme FIA with Sofia $2 - \mathrm { I g } \mathrm { M }$ Performance - Plasma vs. Serum   

<table><tr><td rowspan=2 colspan=2></td><td rowspan=1 colspan=2>Serum IgM</td><td rowspan=2 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Negative</td></tr><tr><td rowspan=2 colspan=1>Plasma IgM</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>129</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>132</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>183</td><td rowspan=1 colspan=1>189</td></tr><tr><td rowspan=1 colspan=2>Total</td><td rowspan=1 colspan=1>135</td><td rowspan=1 colspan=1>186</td><td rowspan=1 colspan=1>321</td></tr></table>

Table 6. Sofia Lyme FIA with Sofia $2 - \mathrm { I g G }$ Performance - Plasma vs. Serum   

<table><tr><td rowspan=2 colspan=2></td><td rowspan=1 colspan=2>Serum IgG</td><td rowspan=2 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Negative</td></tr><tr><td rowspan=2 colspan=1>Plasma IgG</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>86</td><td rowspan=1 colspan=1>12</td><td rowspan=1 colspan=1>98</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>213</td><td rowspan=1 colspan=1>223</td></tr><tr><td rowspan=1 colspan=2>Total</td><td rowspan=1 colspan=1>96</td><td rowspan=1 colspan=1>225</td><td rowspan=1 colspan=1>321</td></tr></table>

2. Comparison studies:

# a. Method comparison with predicate device:

A prospective study was performed using 325 serum samples collected from patients that were submitted for routine Lyme disease testing in the United States. These samples were prospectively collected from nine different clinical sites located in endemic areas of 6 states. Sofia Lyme FIA testing was performed at 3 laboratories, including 1 Quidel site. The predicate Lyme IgM and IgG assays and western blot Lyme IgM and IgG assays were performed at a single laboratory site. First tier results for Sofia Lyme FIA using the Sofia 2 and the predicate assays are shown in Tables 7 and 8.

Table 7. First Tier Lyme IgM Results for Sofia Lyme FIA Tested on Sofia 2 Compared to Predicate Assay   

<table><tr><td rowspan=2 colspan=2></td><td rowspan=1 colspan=3>Predicate Lyme IgM</td><td rowspan=1 colspan=2></td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Equivocal</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>% Agreement</td><td rowspan=1 colspan=1>95% CI</td></tr><tr><td rowspan=2 colspan=1>SofiaIgM</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>57</td><td rowspan=1 colspan=1>18</td><td rowspan=1 colspan=1>46</td><td rowspan=1 colspan=1>PPA{2 =84.3%(75/89)</td><td rowspan=1 colspan=1>75.2% -90.5%</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>91</td><td rowspan=1 colspan=1>190</td><td rowspan=1 colspan=1>NPA = 80.5%(190/236)</td><td rowspan=1 colspan=1>75.0% -85.1%</td></tr><tr><td rowspan=1 colspan=2>Total</td><td rowspan=1 colspan=1>62</td><td rowspan=1 colspan=1>27</td><td rowspan=1 colspan=1>236</td><td rowspan=1 colspan=2></td></tr></table>

1Of the 9 specimens that were Sofia Lyme FIA negative and predicate equivocal, all 9 were negative by western blot 2Four specimens that were negative by the predicate were positive by Sofia Lyme FIA and confirmed positive by western blot

Table 8. First Tier Lyme IgG Results for Sofia Lyme FIA Tested on Sofia 2 Compared to Predicate Assay   

<table><tr><td rowspan=2 colspan=2></td><td rowspan=1 colspan=2>Predicate Lyme IgG</td><td rowspan=1 colspan=2></td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>% Agreement</td><td rowspan=1 colspan=1>95% CI</td></tr><tr><td rowspan=2 colspan=1>Sofia IgG</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>47</td><td rowspan=1 colspan=1>27</td><td rowspan=1 colspan=1>PPA = 90.4% (47 / 52)</td><td rowspan=1 colspan=1>79.0% - 96.3%</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>246</td><td rowspan=1 colspan=1>NPA = 90.1% (246/273)</td><td rowspan=1 colspan=1>86.0% - 93.2%</td></tr><tr><td rowspan=1 colspan=2>Total</td><td rowspan=1 colspan=1>52</td><td rowspan=1 colspan=1>273</td><td rowspan=1 colspan=2></td></tr></table>

# Second-Tier Testing

As recommended by CDC guidelines, second tier Western blot testing was performed on all positive (and equivocal with the predicate assay) samples when tested by either Sofia Lyme FIA or the predicate. The percent agreement between Sofia Lyme FIA and the predicate Lyme test are shown in Tables 9 and 10.

Table 9. IgM Second Tier Testing on Sofia 2   

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Tier 1 +or ±</td><td rowspan=1 colspan=1>IgM WB+</td><td rowspan=1 colspan=1>IgM WB -</td></tr><tr><td rowspan=1 colspan=1>Predicate IgM</td><td rowspan=1 colspan=1>89</td><td rowspan=1 colspan=1>51</td><td rowspan=1 colspan=1>38</td></tr><tr><td rowspan=1 colspan=1>Sofia IgM</td><td rowspan=1 colspan=1>121</td><td rowspan=1 colspan=1>54</td><td rowspan=1 colspan=1>67</td></tr><tr><td rowspan=1 colspan=1>Predicate + Sofia IgM</td><td rowspan=1 colspan=1>75</td><td rowspan=1 colspan=1>50</td><td rowspan=1 colspan=1>25</td></tr></table>

<table><tr><td rowspan=1 colspan=1>1st Tier PPA(95% CI)</td><td rowspan=1 colspan=1>84.3%(75.2-90.5%)</td><td rowspan=1 colspan=1>75/89</td></tr><tr><td rowspan=1 colspan=1>2nd Tier PPA(95% CI)</td><td rowspan=1 colspan=1>98.0%(88.7-99.9%)</td><td rowspan=1 colspan=1>50/51</td></tr></table>

Table 10. IgG Second Tier Testing on Sofia 2   

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Tier 1 +</td><td rowspan=1 colspan=1>IgG WB +</td><td rowspan=1 colspan=1>IgG WB -</td></tr><tr><td rowspan=1 colspan=1>Predicate IgG</td><td rowspan=1 colspan=1>52</td><td rowspan=1 colspan=1>21</td><td rowspan=1 colspan=1>31</td></tr><tr><td rowspan=1 colspan=1>Sofia IgG</td><td rowspan=1 colspan=1>74</td><td rowspan=1 colspan=1>22</td><td rowspan=1 colspan=1>52</td></tr><tr><td rowspan=1 colspan=1>Predicate + Sofia IgG</td><td rowspan=1 colspan=1>47</td><td rowspan=1 colspan=1>21</td><td rowspan=1 colspan=1>26</td></tr></table>

<table><tr><td rowspan=1 colspan=1>1st Tier PPA(95% CI)</td><td rowspan=1 colspan=1>90.4%(79.0-96.3%)</td><td rowspan=1 colspan=1>47/52</td></tr><tr><td rowspan=1 colspan=1>2nd Tier PPA(95% CI)</td><td rowspan=1 colspan=1>100%(81.8-100%)</td><td rowspan=1 colspan=1>21/21</td></tr></table>

# b. Method comparison with original Sofia

The performance of Sofia Lyme FIA when used with Sofia vs. Sofia 2 was compared using a panel of plasma samples at one Quidel site. Panel members were prepared so that a broad range of negative and positive samples were evenly distributed across the dynamic range of the assay, including negative and high negative samples and low, moderate, and high positive samples. The Sofia vs. Sofia 2 comparison results for IgM and IgG are shown below in Tables 11 and 12 respectively.

Table 11. Sofia Lyme FIA – Sofia vs. Sofia 2 Comparison for IgM   

<table><tr><td rowspan=1 colspan=5>TYPE IgM</td></tr><tr><td rowspan=2 colspan=1></td><td rowspan=1 colspan=2>Sofia</td><td rowspan=2 colspan=2></td></tr><tr><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Neg</td></tr><tr><td rowspan=1 colspan=1>Sofia 2 Pos</td><td rowspan=1 colspan=1>105</td><td rowspan=1 colspan=1>11</td><td rowspan=1 colspan=1>PPA(95% CI)</td><td rowspan=1 colspan=1>105/111= 94.6%(88.5% -97.7%)</td></tr><tr><td rowspan=1 colspan=1>Sofia 2 Neg</td><td rowspan=1 colspan=1>6{2</td><td rowspan=1 colspan=1>123</td><td rowspan=1 colspan=1>NPA(95% CI)</td><td rowspan=1 colspan=1>123/124 = 99.2%(94.4% -97.9%)</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>111</td><td rowspan=1 colspan=1>124</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr></table>

1 There was one discordant Sofia 2 positive/ Sofia negative result for IgM which was a high negative specimen. 2 There were six discordant Sofia 2 negative/ Sofia positive results for IgM which were all low positive specimens.

Table 12. Sofia Lyme FIA – Sofia vs. Sofia 2 Comparison for IgG   

<table><tr><td rowspan=1 colspan=5>TYPE IgG</td></tr><tr><td rowspan=2 colspan=1></td><td rowspan=1 colspan=2>Sofia</td><td rowspan=2 colspan=2></td></tr><tr><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Neg</td></tr><tr><td rowspan=1 colspan=1>Sofia 2 Pos</td><td rowspan=1 colspan=1>107</td><td rowspan=1 colspan=1>62</td><td rowspan=1 colspan=1>PPA(95% CI)</td><td rowspan=1 colspan=1>107/110 = 97.3%(91.9% -99.4%)</td></tr><tr><td rowspan=1 colspan=1>Sofia 2 Neg</td><td rowspan=1 colspan=1>32</td><td rowspan=1 colspan=1>119</td><td rowspan=1 colspan=1>NPA(95% CI)</td><td rowspan=1 colspan=1>119/125 = 95.2%(89.7% -98.0%)</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>110</td><td rowspan=1 colspan=1>125</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr></table>

1 There were six discordant Sofia 2 positive/ Sofia negative results for IgG which were all high negative specimens. 2 There were three discordant Sofia 2 negative/ Sofia positive results for IgG which were all low positive specimens.

3. Clinical Studies:

a. Clinical Sensitivity: See K163713   
b. Clinical specificity: N/A   
c. Other clinical supportive data (when a. and b. are not applicable): N/A

# N. Instrument Name:

Sofia 2

# O. System Descriptions:

1. Modes of Operation:

Does the applicant’s device contain the ability to transmit data to a computer, webserver, or mobile device?

Yes ___X___ or No

Does the applicant’s device transmit data to a computer, webserver, or mobile device using wireless transmission?

Yes __X____ or No

2. Software:

FDA has reviewed applicant’s Hazard Analysis and software development processes for this line of product types:

Yes __X____ or No _

P. Other Supportive Instrument Performance Characteristics Data Not Covered in The “Performance Characteristics” Section above:

# Q. Proposed Labeling:

The labeling is sufficient and it satisfies the requirements of 21 CFR Parts 801 and 809, as applicable.

# R. Conclusion:

1. The submitted information in this premarket notification is complete and supports a substantial equivalence decision.